Journal of Clinical Psychopharmacology最新文献

筛选
英文 中文
Tapentadol Withdrawal Dystonia in a Young Adult Male Patient With Opioid Use Disorder. 年轻成年男性阿片类药物使用障碍患者的他他多戒断性肌张力障碍。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2024-11-01 DOI: 10.1097/JCP.0000000000001908
Mahak Aggarwal, Muskan, Jasdeep Kaur, Bharat Udey, Jawahar Singh
{"title":"Tapentadol Withdrawal Dystonia in a Young Adult Male Patient With Opioid Use Disorder.","authors":"Mahak Aggarwal, Muskan, Jasdeep Kaur, Bharat Udey, Jawahar Singh","doi":"10.1097/JCP.0000000000001908","DOIUrl":"https://doi.org/10.1097/JCP.0000000000001908","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":"44 6","pages":"580-581"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fluoxetine and Sertraline Inhibit Height Growth and Growth Hormone Signaling During Puberty. 氟西汀和舍曲林抑制青春期身高增长和生长激素信号传导
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2024-10-14 DOI: 10.1097/JCP.0000000000001922
Chadi Calarge, Chima Amushie, Stephanie Dinh, James A Mills, Sridevi Devaraj, Griselda Barba-Villalobos, Jacqueline Nguyen, Jose M Garcia, Stephanie Sisley, Fida Bacha, Babette Zemel
{"title":"Fluoxetine and Sertraline Inhibit Height Growth and Growth Hormone Signaling During Puberty.","authors":"Chadi Calarge, Chima Amushie, Stephanie Dinh, James A Mills, Sridevi Devaraj, Griselda Barba-Villalobos, Jacqueline Nguyen, Jose M Garcia, Stephanie Sisley, Fida Bacha, Babette Zemel","doi":"10.1097/JCP.0000000000001922","DOIUrl":"10.1097/JCP.0000000000001922","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to examine the effect of fluoxetine and sertraline on height growth and insulin-like growth factor-1 (IGF-1) during puberty.</p><p><strong>Methods: </strong>In this 6-month cohort study, electronic medical records were used to identify 8- to 15-year-old participants, within 1 month of starting fluoxetine (n = 39) or sertraline (n = 27), and sexual maturation stages 2 to 4 were confirmed. Conditions that interfere with height growth led to exclusion. Participants underwent anthropometric assessments and phlebotomy. Healthy, unmedicated children (n = 36) also provided anthropometric data.</p><p><strong>Results: </strong>After the baseline height Z-score, sex, Tanner stage, daily selective serotonin reuptake inhibitor (SSRI) dose, and time were accounted for, the interaction effect of dose by time was inversely associated with height Z-score in SSRI-treated participants (β = -0.18; 95% confidence interval [CI]: -0.35, -0.02). Sertraline and fluoxetine did not differ in their effect on height growth. Compared with being unmedicated, SSRI treatment was associated with a smaller growth in height (time × dose 2-way interaction effect β = -1.30; 95% CI: -2.52, -0.09). The interaction effect of dose by time was significant for body mass index Z-score (β = 0.35; 95% CI: 0.06, 0.64) but not weight Z-score (β = 0.24; 95% CI: -0.01, 0.49). Body mass index Z-score increased more with sertraline compared with fluoxetine (time × dose × SSRI type 3-way interaction effect P < 0.05). SSRI dose was inversely associated with IGF-1 (β = -63.5; 95% CI: -112.2, -14.7) but not insulin growth factor binding protein-3 concentration (β = -207.3; 95% CI: -536.2, 121.5).</p><p><strong>Conclusions: </strong>Fluoxetine and sertraline reduce height gain and IGF-1 concentration, in a dose-dependent manner. Longer-term studies are necessary.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"538-544"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11753947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Valproate Coprescription on Clozapine Pharmacokinetics in Clinical Practice. 丙戊酸共配对氯氮平药动学的影响。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2024-11-01 DOI: 10.1097/JCP.0000000000001923
Robert James Flanagan, Stephen John Obee, Alice Hyun Min Kim, Susanna Every-Palmer
{"title":"Effect of Valproate Coprescription on Clozapine Pharmacokinetics in Clinical Practice.","authors":"Robert James Flanagan, Stephen John Obee, Alice Hyun Min Kim, Susanna Every-Palmer","doi":"10.1097/JCP.0000000000001923","DOIUrl":"https://doi.org/10.1097/JCP.0000000000001923","url":null,"abstract":"<p><strong>Background: </strong>Sodium valproate has been coprescribed with clozapine for seizure prophylaxis and for augmentation in treatment-refractory schizophrenia. However, the effect of valproate on clozapine metabolism and on the incidence of clozapine-related side effects is unclear.</p><p><strong>Methods: </strong>We compared clozapine dose and plasma clozapine and N-desmethylclozapine (norclozapine) concentrations in smokers and nonsmokers of both sexes in samples submitted for clozapine therapeutic drug monitoring, 1996-2017 in relation to valproate coprescription.</p><p><strong>Results: </strong>There were 1217 (665 patients) and 3823 (1600 patients) samples from nonsmokers and from smokers, respectively, who were coprescribed valproate and clozapine. Data from 9774 (5065 patients) and 15,465 (7298 patients) samples from nonsmokers and from smokers, respectively, for whom drugs other than valproate were coprescribed were used as controls. Valproate coprescription in nonsmokers was associated with an increase in average plasma clozapine of 22.5%, suggesting moderate inhibition of clozapine metabolism, but there was no marked effect of valproate coprescription on plasma clozapine in smokers. In all the valproate-treated groups (male and female smokers and nonsmokers), the median plasma norclozapine concentration and the median plasma clozapine-to-norclozapine ratio were significantly lower and higher, respectively, as compared with the controls. Mixed-effects models showed a significant dose-response effect of valproate on lowering the plasma norclozapine concentration and on increasing the plasma clozapine-to-norclozapine ratio.</p><p><strong>Implications: </strong>Given the complexity of the effect of valproate coadministration on clozapine pharmacokinetics and the possibility that the toxicity of clozapine may be enhanced in the presence of valproate, the use of these drugs in combination must now be questioned in all patients and not only in women of childbearing age.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":"44 6","pages":"561-569"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ketamine. The Story of Modern Psychiatry's Most Fascinating Molecule. 氯胺酮。现代精神病学最神奇分子的故事。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2024-10-24 DOI: 10.1097/JCP.0000000000001925
Richard Balon
{"title":"Ketamine. The Story of Modern Psychiatry's Most Fascinating Molecule.","authors":"Richard Balon","doi":"10.1097/JCP.0000000000001925","DOIUrl":"10.1097/JCP.0000000000001925","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"599-600"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of Valbenazine in Elderly and Nonelderly Japanese Patients With Tardive Dyskinesia: A Post Hoc Analysis of the J-KINECT Study. 戊苯那嗪对日本老年和非老年迟发性运动障碍患者的疗效和安全性:J-KINECT 研究的事后分析》。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2024-08-27 DOI: 10.1097/JCP.0000000000001903
Yumi Watanabe, Yutaka Susuta, Mieko Nagano, Hideaki Masui, Nobuhisa Kanahara
{"title":"Efficacy and Safety of Valbenazine in Elderly and Nonelderly Japanese Patients With Tardive Dyskinesia: A Post Hoc Analysis of the J-KINECT Study.","authors":"Yumi Watanabe, Yutaka Susuta, Mieko Nagano, Hideaki Masui, Nobuhisa Kanahara","doi":"10.1097/JCP.0000000000001903","DOIUrl":"10.1097/JCP.0000000000001903","url":null,"abstract":"<p><strong>Purpose: </strong>The efficacy and safety of valbenazine, a selective vesicular monoamine transporter 2 inhibitor, has been confirmed for treatment of tardive dyskinesia (TD) in patients aged ≥65 years in non-Asian clinical trials; however, data are lacking in elderly Asian patients. This post hoc analysis of J-KINECT aimed to evaluate the efficacy and safety of valbenazine in elderly Japanese patients with TD.</p><p><strong>Methods: </strong>J-KINECT was a randomized, double-blind, placebo-controlled study with a 6-week double-blind, placebo-controlled period; 42-week double-blind, valbenazine extension period; and 4-week posttreatment observation period. Outcomes were summarized by age (≥65 years [elderly] and <65 [nonelderly]) and treatment group.</p><p><strong>Results: </strong>The safety analysis set included 100 and 153 patients aged ≥65 and <65 years, respectively (intention-to-treat set: 98 and 151 patients, respectively). In the elderly group, the difference versus placebo in least-squares mean change from baseline in the Abnormal Involuntary Movement Scale total score at week 6 was -3.1 (95% confidence interval: -4.5, -1.7) and -5.5 (-7.0, -3.9) with valbenazine 40 and 80 mg, respectively; in the nonelderly group, respective differences were -1.5 (-2.6, -0.4) and -2.5 (-3.6, -1.3). Both age groups showed improvement in Clinical Global Impression of Change-Tardive Dyskinesia scores with valbenazine. The incidence of treatment-emergent adverse events (TEAEs) leading to treatment discontinuation was higher in the elderly versus nonelderly group. There was no trend toward higher incidences of TEAEs or related TEAEs in the elderly group.</p><p><strong>Conclusions: </strong>The findings suggest that valbenazine may be used effectively and safely as a treatment for TD, even in elderly patients.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"551-560"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bipolar Disorder in a Young Adult With Thalassemia Major With Sequential Development of Neuroleptic Malignant Syndrome and Serotonin Syndrome. 一名患有重型地中海贫血症的青壮年躁郁症患者相继出现神经性恶性综合征和血清素综合征。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2024-10-24 DOI: 10.1097/JCP.0000000000001912
K Ragul Kalaimathi, Manish Roshan Thakur, Bhavuk Garg
{"title":"Bipolar Disorder in a Young Adult With Thalassemia Major With Sequential Development of Neuroleptic Malignant Syndrome and Serotonin Syndrome.","authors":"K Ragul Kalaimathi, Manish Roshan Thakur, Bhavuk Garg","doi":"10.1097/JCP.0000000000001912","DOIUrl":"10.1097/JCP.0000000000001912","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"589-591"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health Alert: Microdose Products Leading to Acute Illness and Hospitalizations Across the United States. 健康警报:微剂量产品在全美导致急性疾病和住院治疗。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2024-09-17 DOI: 10.1097/JCP.0000000000001919
Elisa Nguyen, Abraham Qavi, Minh-Ha Tran
{"title":"Health Alert: Microdose Products Leading to Acute Illness and Hospitalizations Across the United States.","authors":"Elisa Nguyen, Abraham Qavi, Minh-Ha Tran","doi":"10.1097/JCP.0000000000001919","DOIUrl":"10.1097/JCP.0000000000001919","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"576-577"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Buprenorphine-Associated Behavioral and Psychotic Side Effects: A Case Report. 丁丙诺啡相关的行为和精神副作用:病例报告。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2024-08-28 DOI: 10.1097/JCP.0000000000001911
Felix Coid, Aikaterini Dima, Cecilia Livermore, Preety Das, Neeraj Kabra
{"title":"Buprenorphine-Associated Behavioral and Psychotic Side Effects: A Case Report.","authors":"Felix Coid, Aikaterini Dima, Cecilia Livermore, Preety Das, Neeraj Kabra","doi":"10.1097/JCP.0000000000001911","DOIUrl":"10.1097/JCP.0000000000001911","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"584-586"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mirtazapine as a Treatment for Adolescent Depression and PTSD in Juvenile Detention Settings: A Case Report. 米氮平治疗青少年拘留所中的青少年抑郁症和创伤后应激障碍:病例报告。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2024-08-28 DOI: 10.1097/JCP.0000000000001905
Randall Li, Alexia Cicalese, Eric Whitney
{"title":"Mirtazapine as a Treatment for Adolescent Depression and PTSD in Juvenile Detention Settings: A Case Report.","authors":"Randall Li, Alexia Cicalese, Eric Whitney","doi":"10.1097/JCP.0000000000001905","DOIUrl":"10.1097/JCP.0000000000001905","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"581-583"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Suicidal Ideation and Self-harming Thoughts With Valbenazine Use: A Case Report. 使用戊苯那嗪后出现自杀念头和自残想法:病例报告。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2024-11-01 DOI: 10.1097/JCP.0000000000001920
Jake Neeman, Shelby E Lang, Jianwei Jiao
{"title":"Suicidal Ideation and Self-harming Thoughts With Valbenazine Use: A Case Report.","authors":"Jake Neeman, Shelby E Lang, Jianwei Jiao","doi":"10.1097/JCP.0000000000001920","DOIUrl":"10.1097/JCP.0000000000001920","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"596-598"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信